Sorrento Tech (NASDAQ: ROKA) and GenVec (NASDAQ:GNVC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

How to Become a New Pot Stock Millionaire

48.1% of Sorrento Tech shares are owned by institutional investors. Comparatively, 6.2% of GenVec shares are owned by institutional investors. 29.2% of Sorrento Tech shares are owned by insiders. Comparatively, 8.1% of GenVec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Sorrento Tech and GenVec, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Tech 0 0 0 0 N/A
GenVec 0 0 0 0 N/A

Profitability

This table compares Sorrento Tech and GenVec’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sorrento Tech 3.30% 2.05% 1.00%
GenVec -3,748.25% -648.22% -271.77%

Valuation & Earnings

This table compares Sorrento Tech and GenVec’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sorrento Tech $7.24 million 0.45 -$30.78 million ($8.79) -0.07
GenVec N/A N/A N/A ($3.67) N/A

GenVec has lower revenue, but higher earnings than Sorrento Tech. Sorrento Tech is trading at a lower price-to-earnings ratio than GenVec, indicating that it is currently the more affordable of the two stocks.

Summary

Sorrento Tech beats GenVec on 7 of the 8 factors compared between the two stocks.

About Sorrento Tech

Sorrento Tech, Inc., formerly Roka Bioscience, Inc., is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

About GenVec

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Receive News & Ratings for Sorrento Tech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Tech and related companies with MarketBeat.com's FREE daily email newsletter.